RxDoctor Payments Data

Leonid Vorobyev, MD

Psychiatry · Brooklyn, NYNPI 1245259431

Payments from drug & device makers

$4,505in general payments, 2019–2025

Across 102 payments — averaging $44.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$2K
  • AbbVie$472
  • Axsome Therapeutics, Inc.$365
  • Alkermes, Inc.$282
  • Avanir Pharmaceuticals, Inc.$243
  • Lundbeck LLC$203
  • plus $777 from 10 others

What the payments were for

  • Food & beverage$4,46999%
  • Education$371%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,505 in reported general payments places this provider in the 85th percentile of 3,713 psychiatry providers in New York.

See all psychiatry providers in New York

Medicare billing

Part B allowed, 2024
$220,324
Medicare patients
196
Services billed
2,340

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole122$168,678
NamzaricMemantine Hcl/Donepezil Hcl120$66,635
AplenzinBupropion Hbr21$44,803
TrintellixVortioxetine Hydrobromide71$33,463
Wellbutrin XlBupropion Hcl12$28,903
CaplytaLumateperone Tosylate18$27,453
BelsomraSuvorexant33$16,711
Memantine Hcl ErMemantine Hcl140$9,967
Doxepin Hcl166$5,525
Tizanidine Hcl15$4,025
Gabapentin524$3,476
Escitalopram Oxalate332$3,029
Duloxetine Hcl243$2,621
Paliperidone ErPaliperidone32$2,453
Clonazepam268$2,429

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$2,162$168,678122 claims
AbbVieNamzaric$472$66,635120 claims
Bausch Health US, LLCAplenzin$19$44,80321 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$55$33,46371 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$63$27,45318 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,713 psychiatry providers in New York.

Other psychiatry in Brooklyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →